Functional heterogeneity of fibroblasts in primary tumors and metastases.

Trends Cancer

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE, UK. Electronic address:

Published: December 2024

Cancer-associated fibroblasts (CAFs) are abundant components of the tumor microenvironment (TME) of most solid malignancies and have emerged as key regulators of cancer progression and therapy response. Although recent technological advances have uncovered substantial CAF molecular heterogeneity at the single-cell level, defining functional roles for most described CAF populations remains challenging. With the aim of bridging CAF molecular and functional heterogeneity, this review focuses on recently identified functional interactions of CAF subtypes with malignant cells, immune cells, and other stromal cells in primary tumors and metastases. Dissecting the heterogeneous functional crosstalk of specific CAF populations with other components is starting to uncover candidate combinatorial strategies for therapeutically targeting the TME and cancer progression.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2024.11.005DOI Listing

Publication Analysis

Top Keywords

functional heterogeneity
8
primary tumors
8
tumors metastases
8
cancer progression
8
caf molecular
8
caf populations
8
functional
5
caf
5
heterogeneity fibroblasts
4
fibroblasts primary
4

Similar Publications

Neuroplasticity in Diffuse Low-grade Gliomas: Backward Modelling of Brain-tumor Interactions Prior to Diagnosis is Needed to Better Predict Recovery after Treatment.

Curr Neurol Neurosci Rep

January 2025

Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, 80 Avenue Augustin Fliche, Montpellier, 34295, France.

Purpose Of Review: In low-grade glioma (LGG), besides the patient's neurological status and tumor characteristics on neuroimaging, current treatment guidelines mainly rely on the glioma's genetics at diagnosis to define therapeutic strategy, usually starting with surgical resection. However, this snapshot in time does not take into account the antecedent period of tumor progression and its interactions with the brain before presentation. This article reviews new concepts that pertain to reconstruct the history of previous interplay between the LGG's course and adaptive changes in the connectome within which the glioma is embedded over the years preceding the diagnosis.

View Article and Find Full Text PDF

Advancing Drug Development in Myelodysplastic Syndromes.

Blood Adv

December 2024

U.S. Food and Drug Administration, Silver Spring, Maryland, United States.

Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the United States Food and Drug Administration (FDA), (e.g.

View Article and Find Full Text PDF

Background: Stroke is one of the most serious illnesses worldwide and is the primary cause of acquired disability among adults. Post-stroke cognitive impairment (PSCI) is a complication of stroke that significantly impacts patients' daily activities and social functions. Therefore, developing a risk prediction model for PSCI is essential for identifying and preventing disease progression.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands.

Background: There is a strong link between tau and progression of Alzheimer's disease (AD), necessitating an understanding of tau spreading mechanisms. Prior research, predominantly in typical AD, suggested that tau propagates from epicenters (regions with earliest tau) to functionally connected regions. However, given the constrained spatial heterogeneity of tau in typical AD, validating this connectivity-based tau spreading model in AD variants with distinct tau deposition patterns is crucial.

View Article and Find Full Text PDF

Background: Parkinson's (PD) is common and debilitating with over half of patients progressing to postural instability, dementia or death within 10 years. However, onset and rate of progression is highly variable, reflecting heterogeneity in underlying pathology, and biomarker studies to-date have been limited to a single modality or assessed patients with established cognitive impairment.

Method: We assessed multimodal neuroimaging and plasma biomarkers in 98 PD patients (mean disease duration at baseline 4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!